1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma Begins US Distribution of Generic Atopic Dermatitis Ointment

01/11/2022 | 09:08pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
MAYNE PHARMA GROUP LIMITED 1.79% 0.285 Delayed Quote.-5.08%
ON SEMICONDUCTOR CORPORATION 6.04% 56.18 Delayed Quote.-17.29%
All news about MAYNE PHARMA GROUP LIMITED
05/09Mayne pharma announced as recipient of $4.8m federal government grant
AQ
05/09Mayne Pharma Group Secures $3.4 Million Manufacturing Grant
MT
03/22Mayne Pharma Group Limited - NON-EXECUTIVE DIRECTOR APPOINTMENT
AQ
03/21MAYNE PHARMA : 22/03/2022 Non Executive Director Appointment
PU
03/21Ann Custin Accepts to Join the Board and Audit and Risk Committee of Mayne Pharma Group..
CI
03/20MAYNE PHARMA GROUP LIMITED(ASX : MYX) added to S&P/ASX Emerging Companies Index
CI
02/28Mayne pharma reports 1hfy22 results
AQ
02/25Mayne Pharma Group Narrows Loss in Six Monts to December 2021
MT
02/24TRANSCRIPT : Mayne Pharma Group Limited, H1 2022 Earnings Call, Feb 24, 2022
CI
02/24MAYNE PHARMA : 2022 Half Year Investor Presentation
PU
More news
Financials
Sales 2022 403 M 279 M 279 M
Net income 2022 -75,3 M -52,1 M -52,1 M
Net Debt 2022 271 M 187 M 187 M
P/E ratio 2022 -5,96x
Yield 2022 -
Capitalization 494 M 342 M 342 M
EV / Sales 2022 1,90x
EV / Sales 2023 1,66x
Nbr of Employees 967
Free-Float 77,3%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,28 AUD
Average target price 0,36 AUD
Spread / Average Target 27,7%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development